Rizatriptan for acute migraine

Migraine is a significant health problem affecting about 18% of women and 6% of men, and many medicines are available for its treatment. This review assesses the effectiveness of rizatriptan (Maxalt) using data from 3710 patients with migraine. Significant pain relief was achieved within half‐an‐hou...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews 2001-07, Vol.2001 (3)
Main Authors: Oldman, Anna, Smith, Lesley A, McQuay, Henry J, Moore, R Andrew, Derry, Sheena
Format: Article
Language:English
Subjects:
Medicine General & Introductory Medical Sciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3472-980453efa7ab4a9f861484b4271a9048f6f8f0280bf0847c74d707cb7466eb913
cites
container_end_page
container_issue 3
container_start_page
container_title Cochrane database of systematic reviews
container_volume 2001
creator Oldman, Anna
Smith, Lesley A
McQuay, Henry J
Moore, R Andrew
Derry, Sheena
description Migraine is a significant health problem affecting about 18% of women and 6% of men, and many medicines are available for its treatment. This review assesses the effectiveness of rizatriptan (Maxalt) using data from 3710 patients with migraine. Significant pain relief was achieved within half‐an‐hour of taking one 10 mg dose of rizatriptan, (one hour for the 5 mg dose) and continued for at least 24 hours. There was insufficient information in the trial reports to enable meaningful comments to be made about side effects.
doi_str_mv 10.1002/14651858.CD003221.pub2
format article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6564089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6564089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3472-980453efa7ab4a9f861484b4271a9048f6f8f0280bf0847c74d707cb7466eb913</originalsourceid><addsrcrecordid>eNpVzs1Kw0AUhuFBEFurt1ByA4lzZk7mZyNI1CoUBFFwF86kM3Wk-WGSCnr1BnTj6ls88PEytgZeAOfiClCVYEpTVLecSyGgGI5OnLDlDDZHK98W7HwcP2a0AOaMLUArqTToJVs_x2-aUhwm6rLQp4ya4-SzNu4Txc5fsNNAh9Ff_u2Kvd7fvVQP-fZp81jdbPNGoha5NRxL6QNpckg2GAVo0KHQQJajCSqYwIXhLnCDutG401w3TqNS3lmQK3b9-zuXt37X-G5KdKiHFFtKX3VPsf4vXXyv9_1nrUqF3Fj5A_3oSy8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Rizatriptan for acute migraine</title><source>Alma/SFX Local Collection</source><creator>Oldman, Anna ; Smith, Lesley A ; McQuay, Henry J ; Moore, R Andrew ; Derry, Sheena</creator><creatorcontrib>Oldman, Anna ; Smith, Lesley A ; McQuay, Henry J ; Moore, R Andrew ; Derry, Sheena</creatorcontrib><description>Migraine is a significant health problem affecting about 18% of women and 6% of men, and many medicines are available for its treatment. This review assesses the effectiveness of rizatriptan (Maxalt) using data from 3710 patients with migraine. Significant pain relief was achieved within half‐an‐hour of taking one 10 mg dose of rizatriptan, (one hour for the 5 mg dose) and continued for at least 24 hours. There was insufficient information in the trial reports to enable meaningful comments to be made about side effects.</description><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD003221.pub2</identifier><identifier>PMID: 17636717</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Medicine General &amp; Introductory Medical Sciences</subject><ispartof>Cochrane database of systematic reviews, 2001-07, Vol.2001 (3)</ispartof><rights>Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd. 2019 The Cochrane Collaboration</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3472-980453efa7ab4a9f861484b4271a9048f6f8f0280bf0847c74d707cb7466eb913</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Oldman, Anna</creatorcontrib><creatorcontrib>Smith, Lesley A</creatorcontrib><creatorcontrib>McQuay, Henry J</creatorcontrib><creatorcontrib>Moore, R Andrew</creatorcontrib><creatorcontrib>Derry, Sheena</creatorcontrib><title>Rizatriptan for acute migraine</title><title>Cochrane database of systematic reviews</title><description>Migraine is a significant health problem affecting about 18% of women and 6% of men, and many medicines are available for its treatment. This review assesses the effectiveness of rizatriptan (Maxalt) using data from 3710 patients with migraine. Significant pain relief was achieved within half‐an‐hour of taking one 10 mg dose of rizatriptan, (one hour for the 5 mg dose) and continued for at least 24 hours. There was insufficient information in the trial reports to enable meaningful comments to be made about side effects.</description><subject>Medicine General &amp; Introductory Medical Sciences</subject><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpVzs1Kw0AUhuFBEFurt1ByA4lzZk7mZyNI1CoUBFFwF86kM3Wk-WGSCnr1BnTj6ls88PEytgZeAOfiClCVYEpTVLecSyGgGI5OnLDlDDZHK98W7HwcP2a0AOaMLUArqTToJVs_x2-aUhwm6rLQp4ya4-SzNu4Txc5fsNNAh9Ff_u2Kvd7fvVQP-fZp81jdbPNGoha5NRxL6QNpckg2GAVo0KHQQJajCSqYwIXhLnCDutG401w3TqNS3lmQK3b9-zuXt37X-G5KdKiHFFtKX3VPsf4vXXyv9_1nrUqF3Fj5A_3oSy8</recordid><startdate>20010723</startdate><enddate>20010723</enddate><creator>Oldman, Anna</creator><creator>Smith, Lesley A</creator><creator>McQuay, Henry J</creator><creator>Moore, R Andrew</creator><creator>Derry, Sheena</creator><general>John Wiley &amp; Sons, Ltd</general><scope>5PM</scope></search><sort><creationdate>20010723</creationdate><title>Rizatriptan for acute migraine</title><author>Oldman, Anna ; Smith, Lesley A ; McQuay, Henry J ; Moore, R Andrew ; Derry, Sheena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3472-980453efa7ab4a9f861484b4271a9048f6f8f0280bf0847c74d707cb7466eb913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Medicine General &amp; Introductory Medical Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oldman, Anna</creatorcontrib><creatorcontrib>Smith, Lesley A</creatorcontrib><creatorcontrib>McQuay, Henry J</creatorcontrib><creatorcontrib>Moore, R Andrew</creatorcontrib><creatorcontrib>Derry, Sheena</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oldman, Anna</au><au>Smith, Lesley A</au><au>McQuay, Henry J</au><au>Moore, R Andrew</au><au>Derry, Sheena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rizatriptan for acute migraine</atitle><jtitle>Cochrane database of systematic reviews</jtitle><date>2001-07-23</date><risdate>2001</risdate><volume>2001</volume><issue>3</issue><eissn>1469-493X</eissn><abstract>Migraine is a significant health problem affecting about 18% of women and 6% of men, and many medicines are available for its treatment. This review assesses the effectiveness of rizatriptan (Maxalt) using data from 3710 patients with migraine. Significant pain relief was achieved within half‐an‐hour of taking one 10 mg dose of rizatriptan, (one hour for the 5 mg dose) and continued for at least 24 hours. There was insufficient information in the trial reports to enable meaningful comments to be made about side effects.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>17636717</pmid><doi>10.1002/14651858.CD003221.pub2</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1469-493X
ispartof Cochrane database of systematic reviews, 2001-07, Vol.2001 (3)
issn 1469-493X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6564089
source Alma/SFX Local Collection
subjects Medicine General & Introductory Medical Sciences
title Rizatriptan for acute migraine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T03%3A05%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rizatriptan%20for%20acute%20migraine&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Oldman,%20Anna&rft.date=2001-07-23&rft.volume=2001&rft.issue=3&rft.eissn=1469-493X&rft_id=info:doi/10.1002/14651858.CD003221.pub2&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6564089%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3472-980453efa7ab4a9f861484b4271a9048f6f8f0280bf0847c74d707cb7466eb913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/17636717&rfr_iscdi=true